Nina Niu Sanford: New NCCN guidelines for pMMR T3+/N+ rectal cancer
Nina Niu Sanford shared a post on X:
“New National Comprehensive Cancer Network (NCCN) guidelines recommend total neoadjuvant therapy for all pMMR T3+/N+ rectal cancer.
What about upfront surgery for ‘lower risk’ tumors?
Several series show low LR rates with surgery 1st, and both American Society for Radiation Oncology (ASTRO) and European Society for Medical Oncology (ESMO) recommendation for tumors fitting criteria.
Total neoadjuvant therapy (TNT) makes sense for many but not all IMO.”
Source: Nina Niu Sanford/X
Nina Niu Sanford is an Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital. She specializes in treating gastrointestinal cancers and actively participates in clinical trials combining high-dose radiation therapy with immunotherapy. Additionally, she researches healthcare access disparities and conducts pan-cancer outcomes research using large databases.
